Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of (3H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats

Current Therapeutic Research - Clinical and Experimental

Volumn 67, Issue 6, 2006, Pages 406-419

  Pérez, L Yohani ^a   Menéndez, Roberto ^a   Más, Rosa ^a   González, Rosa M ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

D 004; oleic acid pharmacokinetics; royal palm lipid extract; Roystonea regia lipid extract

Indexed keywords

D 004; LIPID; OLEIC ACID; PLANT EXTRACT; TRITIUM; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADRENAL GLAND; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARECACEAE; ARTICLE; BLOOD SAMPLING; BRAIN; CENTRIFUGATION; CONTROL GROUP; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; EXPERIMENTAL STUDY; FECES; FRUIT; HALF LIFE TIME; IMMUNOBLOTTING; KIDNEY; LARGE INTESTINE; LIVER; LUNG; MAXIMUM PLASMA CONCENTRATION; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; RAT; ROYSTONEA REGIA; SEMINAL VESICLE; SINGLE DRUG DOSE; SMALL INTESTINE; SPLEEN; STOMACH; TESTIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE HOMOGENATE; URINALYSIS;

EID: 34249950824     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2006.12.005     Document Type: Article

References (31)

1. Clifford G.M., and Farmer R.D. Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur Urol. 38 (2000) 2-19
2. Simpson R.J. Benign prostatic hyperplasia. An overview of epidemiology and treatment. Primary Care in the New NHS. (2001) 184-186
3. [published correction appears in BMJ. 2002;324:775]. Barry M.J., and Roehrborn C.G. Benign prostatic hyperplasia. BMJ 323 (2001) 1042-1046
4. [published correction appears in Lancet. 2003;362:496]. Thorpe A., and Neal D. Benign prostatic hyperplasia. Lancet 361 (2003) 1359-1367
5. Bhargava S., Canda A.E., and Chapple C.R. A rational approach to benign prostatic hyperplasia evaluation: Recent advances. Curr Opin Urol. 14 (2004) 1-6
6. Sandhu J.S., and Te A.E. The role of 5 alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr Urol Rep. 5 (2004) 274-279
7. Oelke M., Hofner K., Berges R.R., and Jonas U. Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results [in German]. Urologe A 41 (2002) 425-441
8. Lowe F.C., Dreikorn K., Borkowski A., et al. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 37 (1998) 187-193
9. Plosker G.L., and Brogden R.N. Serenoa repens (permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 9 (1996) 379-395
10. Bombardelli E., Morazzoni P., and Small J.K. Serenoa repens (bartram). Fitoterapia 68 (1997) 99-113
11. [published correction appears in JAMA. 1999;281: 515]. Wilt T.J., Ishani A., Stark G., et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. JAMA 280 (1998) 1604-1609
12. Fructus Serenoa repentis. WHO monographs on selected medicinal plants (2000) 285-299
13. No. 2. Saw palmetto extract. Publication no. USP28-NF23. Expert Committee. United States pharmacopeial forum: (DSB) dietary supplement: Botanicals Vol. 28. (2005), Pharmacopeial Convention, Rockville, Md 425
14. Wilt T., Ishani A., Stark G., et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2 (2000) CD001423
15. Aliaev I.G., Vinarov A.Z., Lokshin K.L., and Spivak L.G. Five-year experience in treating patients with permixone (Serenoa repens "Pierre Fabre Medicament") [in Russian]. Urologiia 1 (2002) 23-25
16. Gordon A.E., and Shaughnessy A.F. Saw palmetto for prostate disorders. Am Fam Physician 67 (2003) 1281-1283
17. Chevalier G., Benard P., Cousse H., and Bengone T. Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (permixon) supplemented with [1-14C]-lauric acid, [1-14C]-oleic acid or [4-14C]-betasitosterol. Eur J Drug Metab Pharmacokinet. 22 (1997) 73-83
18. De Bernardi Di Valserra M., Tripodi A.S., Contos S., and Germogli R. Serenoa repens capsules: A bioequivalence study. Acta Toxicol Ther. 15 (1994) 21-39
19. Arruzazabala M.L., Carbajal D., Mas R., et al. Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on testosterone-induced prostate hyperplasia in intact and castrated rodents. Drugs Exp Clin Res. 30 (2004) 227-233
20. Carbajal D., Arruzazabala M.D.L., Más R., et al. Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostate hypertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled study. Curr Ther Res Clin Exp. 65 (2004) 505-514
21. Noa M., Arruzazabala M.L., Carbajal D., et al. Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats. Int J Tissue React. 27 (2005) 203-211
22. Carbajal D., Molina V., Mas R., and Arruzazabala M.L. Therapeutic effect of D-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exp Clin Res. 31 (2005) 193-197
23. Raynaud J.P., Cousse H., and Martin P.M. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of permixon. J Steroid Biochem Mol Biol. 82 (2002) 233-239
24. Stremmel W. Uptake of fatty acids by jejunal mucosal cells is mediated by a fatty acid binding membrane protein. J Clin Invest. 82 (1988) 2001-2010
25. Stahl A., Hirsch D.J., Gimeno R.E., et al. Identification of the major intestinal fatty acid transport protein. Mol Cell. 4 (1999) 299-308
26. Chaves C.R., Elias P.R., Cheng W., et al. Long chain fatty acid uptake by human intestinal mucosa in vitro: Mechanisms of transport. Digestion 67 (2003) 32-36
27. Murota K., Matsui N., Kawada T., et al. Influence of fatty alcohol and other fatty acid derivatives on fatty acid uptake into rat intestinal epithelial cells. Lipids 36 (2001) 21-26
28. Holehouse E.L., Liu M.L., and Aponte G.W. Oleic acid distribution in small intestinal epithelial cells expressing intestinal-fatty acid binding protein. Biochern Biophys Acta 1390 (1998) 52-64
29. Schwieterman W., Sorrentino D., Potter B.J., et al. Uptake of oleate by isolated rat adipocytes is mediated by a 40-kDa plasma membrane fatty acid binding protein closely related to that in liver and gut. Proc Natl Acad Sci USA 85 (1988) 359-363
30. Rabinowitz J.L., and Myerson R.M. Changes in the lipid content of rat lymph after the ingestion of [14C] long-chain fatty acids. Life Sci. 54 (1994) 555-559
31. Bookstaff R.C., PaiBir S., Bharaj S.S., et al. The safety and the use of ethyl oleate in food is supported by metabolism data in rats and clinical safety data in humans. Regul Toxicol Pharmacol. 37 (2003) 133-148